Gynecological cancers (including breast, ovarian, cervical, and endometrial cancer) and gastrointestinal cancers (including gastric, colorectal, liver, and pancreatic cancer) are the most common cancer types worldwide. Although chemotherapy, radiotherapy, and surgical excision are commonly used to treat these gynecological and gastrointestinal cancers, cancer cells often become resistant to conventional cancer therapy due to many different mechanisms. Accordingly, new therapeutic strategies such as the identification of novel potential molecular targets or biomarkers, as well as the development of new molecular diagnostic approaches and targeted therapy (e.g., protein, transcription factor, non-coding RNA, targeted small-molecule drugs, etc.) are greatly needed to overcome inherent and acquired resistance, which would provide a promising therapeutic approach for the treatment of gynecological and gastrointestinal cancers.
This Research Topic aims to provide updates on the screening and identification of novel molecular targets or biomarkers and discuss the recent advances in developing new technologies for molecular diagnosis, prognosis, and targeted therapy in gynecological and gastrointestinal cancers.
We accept Original Research Articles, Reviews, and Mini-Reviews highlighting the latest advances in research on gynecological and gastrointestinal cancers. Topics of interest include but are not limited to the following:
• Discovery and identification of novel molecular targets and biomarkers in gynecological and gastrointestinal cancers
• Development of novel molecular diagnostic approaches for gynecological and gastrointestinal cancers
• Drug repurposing study for the treatment of gynecological and gastrointestinal cancers
• Mechanistic aspects underlying the drug resistance in gynecological and gastrointestinal cancers
• Discovery of novel small-molecule drugs for the treatment of gynecological and gastrointestinal cancers
Gynecological cancers (including breast, ovarian, cervical, and endometrial cancer) and gastrointestinal cancers (including gastric, colorectal, liver, and pancreatic cancer) are the most common cancer types worldwide. Although chemotherapy, radiotherapy, and surgical excision are commonly used to treat these gynecological and gastrointestinal cancers, cancer cells often become resistant to conventional cancer therapy due to many different mechanisms. Accordingly, new therapeutic strategies such as the identification of novel potential molecular targets or biomarkers, as well as the development of new molecular diagnostic approaches and targeted therapy (e.g., protein, transcription factor, non-coding RNA, targeted small-molecule drugs, etc.) are greatly needed to overcome inherent and acquired resistance, which would provide a promising therapeutic approach for the treatment of gynecological and gastrointestinal cancers.
This Research Topic aims to provide updates on the screening and identification of novel molecular targets or biomarkers and discuss the recent advances in developing new technologies for molecular diagnosis, prognosis, and targeted therapy in gynecological and gastrointestinal cancers.
We accept Original Research Articles, Reviews, and Mini-Reviews highlighting the latest advances in research on gynecological and gastrointestinal cancers. Topics of interest include but are not limited to the following:
• Discovery and identification of novel molecular targets and biomarkers in gynecological and gastrointestinal cancers
• Development of novel molecular diagnostic approaches for gynecological and gastrointestinal cancers
• Drug repurposing study for the treatment of gynecological and gastrointestinal cancers
• Mechanistic aspects underlying the drug resistance in gynecological and gastrointestinal cancers
• Discovery of novel small-molecule drugs for the treatment of gynecological and gastrointestinal cancers
